Oxford Biomedica (OXB) Competitors

Genus (LON:GNS) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Which has more risk & volatility, GNS or OXB?

Genus has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Do analysts rate GNS or OXB?

Genus currently has a consensus price target of GBX 2,150, indicating a potential upside of 13.76%. Oxford Biomedica has a consensus price target of GBX 560, indicating a potential upside of 80.06%. Given Oxford Biomedica's higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has preferable earnings and valuation, GNS or OXB?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£666.67M	1.86	£7.87M	£12.06	156.66
Oxford Biomedica	£98.31M	3.36	-£143.51M	-£134.59	-2.31

Do insiders and institutionals have more ownership in GNS or OXB?

77.8% of Genus shares are held by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are held by institutional investors. 0.8% of Genus shares are held by company insiders. Comparatively, 21.2% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer GNS or OXB?

Oxford Biomedica received 7 more outperform votes than Genus when rated by MarketBeat users. However, 70.54% of users gave Genus an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Genus	Outperform Votes 352 70.54%	Underperform Votes 147 29.46%
Oxford Biomedica	Outperform Votes 359 66.73%	Underperform Votes 179 33.27%

Does the media prefer GNS or OXB?

In the previous week, Genus and Genus both had 1 articles in the media. Oxford Biomedica's average media sentiment score of 1.14 beat Genus' score of 1.11 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GNS or OXB more profitable?

Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -145.98%. Genus' return on equity of 1.41% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	1.18%	1.41%	3.31%
Oxford Biomedica	-145.98%	-202.50%	-12.67%

Summary

Genus beats Oxford Biomedica on 11 of the 17 factors compared between the two stocks.